+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Syncytial Virus Vaccine for the Elderly Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Respiratory Syncytial Virus Vaccine for the Elderly Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Respiratory Syncytial Virus Vaccine for the Elderly Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6081818
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Respiratory syncytial virus poses a critical threat to adults aged 60 and above, driving elevated hospitalization and mortality rates across healthcare systems. Declining immune function in elderly cohorts amplifies susceptibility, leading to exacerbated outcomes when RSV infection occurs concurrently with chronic comorbidities. The pressing need for targeted immunization strategies is underscored by rising incidence during seasonal peaks and a gap in approved preventive measures for this demographic. Recent advances in immunology, molecular biology, and adjuvant technology have accelerated the development of vaccine candidates specifically designed for older adults, offering hope for reducing disease burden and healthcare costs. This executive summary synthesizes key industry trends, regulatory influences, tariff impacts, segmentation frameworks, regional dynamics, and competitive landscapes. It also provides actionable guidance for stakeholders aiming to navigate complex market conditions and optimize strategic positioning in the evolving field of elderly RSV vaccination.

Transformative Shifts Reshaping the RSV Vaccine Landscape

The RSV vaccine landscape has undergone transformative shifts driven by breakthroughs in RNA-based platforms and recombinant protein technologies, which now vie alongside traditional inactivated and live attenuated formulations. Regulatory agencies are adopting accelerated approval pathways and adaptive trial designs to address urgent public health needs, while manufacturers forge public-private partnerships to mitigate development risk and share resources. Epidemiological patterns have shifted with an aging global population, spurring payors and providers to prioritize preventive immunization over reactive care. Supply chains are evolving toward greater resilience and geographic diversification, leveraging domestic manufacturing incentives and distributed production networks. Digital health solutions-from remote patient monitoring to electronic immunization registries-are enhancing uptake tracking and real-world evidence generation. In tandem, rising consumer awareness and stakeholder demand for differentiated dosing schedules, route options, and component safety profiles have elevated market complexity. These combined dynamics are redefining competitive advantage and reshaping investment priorities across the RSV vaccine ecosystem.

Evaluating the 2025 United States Tariffs Impact on RSV Vaccines

United States tariff measures introduced in 2025 have imposed additional duties on key vaccine raw materials-ranging from specialized adjuvant precursors to proprietary stabilizer compounds-elevating per-dose production costs for both domestic and imported products. Manufacturers have responded by reassessing global sourcing strategies, relocating certain manufacturing steps to tariff-exempt jurisdictions and negotiating long-term supply contracts to hedge price volatility. The increased cost burden has prompted discussions around price adjustments with payors and spurred investments in on-shore bioprocessing capabilities to secure seamless access to critical inputs. Import tariffs on finished vaccine shipments have also influenced distribution priorities, incentivizing higher local fill-finish activity and strategic partnerships with contract development and manufacturing organizations. Regulatory bodies are monitoring these developments closely, evaluating the impact on vaccine affordability and supply continuity. As a result, stakeholders face a delicate balance between maintaining cost-effective production, ensuring broad patient access, and complying with evolving trade policies.

Comprehensive Segmentation Insights Informing Targeted Strategies

The market’s multidimensional segmentation provides the foundation for precision targeting and resource allocation. Formulation analysis distinguishes inactivated vaccines from live attenuated alternatives, alongside recombinant platforms subdivided into protein-based constructs and virus-like particles. Administration routes span injectable formulations, intranasal sprays and emerging oral vaccines, each catering to varying patient preferences and adherence profiles. Dosage considerations contrast single-dose regimens with multiple-dose protocols that incorporate booster shot strategies to optimize immune memory. Component-level segmentation examines the role of adjuvants in enhancing immunogenicity, antibiotic-free formulations such as neomycin-free or polymyxin-free variants, preservative profiles including alcohol-free or mercury-free systems, and stabilizers composed of amino acids or sugar matrices. End-user segmentation captures delivery channels from home healthcare and acute care hospitals to nursing homes, retail pharmacies and primary care clinics. Disease burden stratification highlights high-risk subgroups with cardiovascular conditions, chronic respiratory illnesses like asthma or COPD, and immunocompromised individuals. Age cohorts are refined across 60-69, 70-79 and 80+ years. Distribution channels differentiate hospital pharmacies, online platforms and retail outlets. Technological categories contrast advanced biotech innovations-such as nanotechnology-with conventional and synthetic strategies. Vaccine typology distinguishes prophylactic from therapeutic applications, while manufacturing segmentation contrasts advanced genetic techniques with traditional methods, guiding capacity planning and investment decisions.

Regional Dynamics Influencing RSV Vaccine Adoption and Distribution

Regional dynamics are shaping both demand and supply for RSV vaccines in seniors. In the Americas, established reimbursement frameworks and broad public health campaigns drive high vaccination awareness, supported by strong manufacturing infrastructure and strategic partnerships with government agencies. Europe, Middle East and Africa benefit from regulatory harmonization under EMEA guidelines, robust pharmacovigilance systems and collaborative funding models that encourage multi-country clinical trials and equitable access initiatives. Asia-Pacific displays rapid growth potential due to expanding geriatric populations, rising healthcare expenditures and emerging domestic vaccine producers leveraging cost-effective platforms. Local regulatory authorities are increasingly aligning with ICH standards, facilitating faster approvals, while public-private alliances are investing in regional fill-finish facilities to reduce import dependency. Each region’s unique combination of policy environment, population demographics and industrial capacity informs tailored go-to-market strategies.

Leading Industry Players Advancing RSV Vaccine Development

A diverse set of industry leaders and innovators is advancing RSV vaccine development for elderly populations. Ablynx and Sanofi S.A. focus on protein-based recombinant constructs, while AstraZeneca Plc in collaboration with Sanofi and its subsidiary MedImmune apply virus-like particle technology. Bavarian Nordic A/S leverages viral vector platforms as a complementary approach to Codagenix, Inc.’s live attenuated candidates. GlaxoSmithKline plc integrates novel adjuvant systems in its pipeline alongside Johnson & Johnson’s Janssen Pharmaceuticals division, which continues to evaluate viral vector strategies. Meissa Vaccines, Inc. pursues intranasal delivery to enhance mucosal immunity, whereas Merck & Co., Inc. and Moderna, Inc. spearhead RNA-based formulations. Novavax, Inc. and Pfizer Inc. optimize nanoparticle and virus-like constructs for enhanced antigen presentation. ReVax Ltd. and ReViral Ltd. are developing next-generation adjuvanted therapies with a therapeutic orientation. Valneva SE advances traditional inactivated solutions, while Vaxart, Inc. champions oral tablet delivery for improved patient compliance. Zydus Cadila applies synthetic strategy innovations to broaden platform resilience. These players collaborate with academic institutions, contract manufacturing organizations and regulatory bodies to accelerate clinical development, streamline submissions and optimize manufacturing agility. Their collective expertise spans advanced genetic techniques, conventional bioprocessing and cutting-edge nanotechnology, ensuring a robust and competitive pipeline.

Actionable Strategies for Industry Leaders to Drive RSV Vaccine Success

Industry leaders should prioritize strategic investments in next-generation platforms such as RNA and virus-like particle technologies to achieve superior immunogenicity in elderly cohorts. Establishing flexible manufacturing networks-including modular, single-use facilities and localized fill-finish operations-can mitigate trade policy risks and ensure supply continuity. Forging alliances with academic centers and biotech innovators accelerates candidate qualification and leverages specialized expertise. Early engagement with regulatory authorities to adopt adaptive trial designs and streamlined approval pathways will reduce time-to-market. Tailored Go-To-Market strategies informed by segmentation data-spanning formulation preferences, administration routes and end-user channels-will enhance uptake and adherence. Leveraging digital health tools for real-world evidence generation and patient engagement can fortify value dossiers for payor negotiations. Pricing frameworks should reflect regional economic variances while maintaining affordability for high-risk populations. Finally, robust risk-management protocols, including dual sourcing of critical inputs and scenario planning for tariff shifts, will safeguard operations against supply chain disruptions.

Conclusion Solidifying the Path Forward in Elderly RSV Vaccination

The convergence of advanced vaccine technologies, evolving regulatory landscapes and shifting trade policies presents both challenges and opportunities in the elderly RSV vaccine sector. A rigorous, segment-informed approach is essential for aligning product profiles with patient needs, payer expectations and regional dynamics. Collaborative efforts among manufacturers, public health agencies and academic research institutions will accelerate clinical innovation and de-risk development pathways. Supply chain resilience-achieved through geographic diversification and flexible manufacturing modalities-will be critical in navigating tariff impacts and demand fluctuations. By implementing the recommended strategic imperatives, stakeholders can reinforce their competitive positioning, optimize resource allocation and ultimately deliver safe, effective immunization solutions that address the substantial health burden of RSV in older adults.

Market Segmentation & Coverage

This research report categorizes the Respiratory Syncytial Virus Vaccine for the Elderly Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Recombinant Vaccines
    • Protein-Based
    • Virus-Like Particles
  • RNA-Based Vaccines
  • Injectable Vaccines
  • Nasal Sprays
  • Oral Vaccines
  • Multiple Dosages
    • Booster Shots
  • Single Dose
  • Adjuvants
  • Antibiotics
    • Neomycin-Free
    • Polymyxin-Free
  • Preservatives
    • Alcohol-Free
    • Mercury-Free
  • Stabilizers
    • Amino Acids
    • Sugars
  • Home Healthcare
  • Hospitals
  • Nursing Homes
  • Pharmacies
  • Primary Care Clinics
  • Cardiovascular Conditions
  • Chronic Respiratory Conditions
    • Asthma
    • Chronic Obstructive Pulmonary Disease
  • Weakened Immune Systems
  • 60-69 Years
  • 70-79 Years
  • 80+ Years
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Biotech Innovations
    • Nanotechnology
  • Conventional Technology
  • Synthetic Strategies
  • Prophylactic
  • Therapeutic
  • Advanced Genetic Techniques
  • Traditional Methods

This research report categorizes the Respiratory Syncytial Virus Vaccine for the Elderly Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Respiratory Syncytial Virus Vaccine for the Elderly Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Ablynx (A Sanofi Company)
  • AstraZeneca Plc (In collaboration with Sanofi)
  • Bavarian Nordic A/S
  • Codagenix, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • MedImmune (A subsidiary of AstraZeneca)
  • Meissa Vaccines, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • ReVax Ltd.
  • ReViral Ltd.
  • Sanofi S.A.
  • Valneva SE
  • Vaxart, Inc.
  • Zydus Cadila

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Vaccine Formulation
8.1. Introduction
8.2. Inactivated Vaccines
8.3. Live Attenuated Vaccines
8.4. Recombinant Vaccines
8.4.1. Protein-Based
8.4.2. Virus-Like Particles
8.5. RNA-Based Vaccines
9. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Administration Route
9.1. Introduction
9.2. Injectable Vaccines
9.3. Nasal Sprays
9.4. Oral Vaccines
10. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Vaccine Dosage
10.1. Introduction
10.2. Multiple Dosages
10.2.1. Booster Shots
10.3. Single Dose
11. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Vaccine Components
11.1. Introduction
11.2. Adjuvants
11.3. Antibiotics
11.3.1. Neomycin-Free
11.3.2. Polymyxin-Free
11.4. Preservatives
11.4.1. Alcohol-Free
11.4.2. Mercury-Free
11.5. Stabilizers
11.5.1. Amino Acids
11.5.2. Sugars
12. Respiratory Syncytial Virus Vaccine for the Elderly Market, by End-User
12.1. Introduction
12.2. Home Healthcare
12.3. Hospitals
12.4. Nursing Homes
12.5. Pharmacies
12.6. Primary Care Clinics
13. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Disease Burden
13.1. Introduction
13.2. Cardiovascular Conditions
13.3. Chronic Respiratory Conditions
13.3.1. Asthma
13.3.2. Chronic Obstructive Pulmonary Disease
13.4. Weakened Immune Systems
14. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Age Group
14.1. Introduction
14.2. 60-69 Years
14.3. 70-79 Years
14.4. 80+ Years
15. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Distribution Channel
15.1. Introduction
15.2. Hospital Pharmacies
15.3. Online Pharmacies
15.4. Retail Pharmacies
16. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Technology
16.1. Introduction
16.2. Biotech Innovations
16.2.1. Nanotechnology
16.3. Conventional Technology
16.4. Synthetic Strategies
17. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Vaccine Type
17.1. Introduction
17.2. Prophylactic
17.3. Therapeutic
18. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Manufacturing Process
18.1. Introduction
18.2. Advanced Genetic Techniques
18.3. Traditional Methods
19. Americas Respiratory Syncytial Virus Vaccine for the Elderly Market
19.1. Introduction
19.2. Argentina
19.3. Brazil
19.4. Canada
19.5. Mexico
19.6. United States
20. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market
20.1. Introduction
20.2. Australia
20.3. China
20.4. India
20.5. Indonesia
20.6. Japan
20.7. Malaysia
20.8. Philippines
20.9. Singapore
20.10. South Korea
20.11. Taiwan
20.12. Thailand
20.13. Vietnam
21. Europe, Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Market
21.1. Introduction
21.2. Denmark
21.3. Egypt
21.4. Finland
21.5. France
21.6. Germany
21.7. Israel
21.8. Italy
21.9. Netherlands
21.10. Nigeria
21.11. Norway
21.12. Poland
21.13. Qatar
21.14. Russia
21.15. Saudi Arabia
21.16. South Africa
21.17. Spain
21.18. Sweden
21.19. Switzerland
21.20. Turkey
21.21. United Arab Emirates
21.22. United Kingdom
22. Competitive Landscape
22.1. Market Share Analysis, 2024
22.2. FPNV Positioning Matrix, 2024
22.3. Competitive Analysis
22.3.1. Ablynx (A Sanofi Company)
22.3.2. AstraZeneca Plc (In collaboration with Sanofi)
22.3.3. Bavarian Nordic A/S
22.3.4. Codagenix, Inc.
22.3.5. GlaxoSmithKline plc
22.3.6. Johnson & Johnson (Janssen Pharmaceuticals)
22.3.7. MedImmune (A subsidiary of AstraZeneca)
22.3.8. Meissa Vaccines, Inc.
22.3.9. Merck & Co., Inc.
22.3.10. Moderna, Inc.
22.3.11. Novavax, Inc.
22.3.12. Pfizer Inc.
22.3.13. ReVax Ltd.
22.3.14. ReViral Ltd.
22.3.15. Sanofi S.A.
22.3.16. Valneva SE
22.3.17. Vaxart, Inc.
22.3.18. Zydus Cadila
23. ResearchAI
24. ResearchStatistics
25. ResearchContacts
26. ResearchArticles
27. Appendix
List of Figures
FIGURE 1. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET MULTI-CURRENCY
FIGURE 2. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET MULTI-LANGUAGE
FIGURE 3. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2024 VS 2030 (%)
FIGURE 18. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 22. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 24. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 26. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
FIGURE 28. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 32. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 36. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 37. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 38. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PROTEIN-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VIRUS-LIKE PARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY INJECTABLE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY NASAL SPRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ORAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BOOSTER SHOTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY NEOMYCIN-FREE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY POLYMYXIN-FREE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ALCOHOL-FREE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MERCURY-FREE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AMINO ACIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY SUGARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY NURSING HOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY WEAKENED IMMUNE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY 60-69 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY 70-79 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY 80+ YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CONVENTIONAL TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY SYNTHETIC STRATEGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADVANCED GENETIC TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TRADITIONAL METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 125. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 126. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 127. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 128. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 129. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 130. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 131. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 132. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 133. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 134. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 136. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 137. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 138. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 141. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 142. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 143. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 144. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 145. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 146. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 147. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 148. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 150. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 151. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 152. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 154. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 159. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 160. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 217. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 218. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 219. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 220. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 221. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 222. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 223. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 224. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 225. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 226. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 227. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 228. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 229. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 230. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 233. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 234. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 235. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE FORMULATION, 2018-2030 (USD MILLION)
TABLE 236. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY RECOMBINANT VACCINES, 2018-2030 (USD MILLION)
TABLE 237. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 238. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE DOSAGE, 2018-2030 (USD MILLION)
TABLE 239. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MULTIPLE DOSAGES, 2018-2030 (USD MILLION)
TABLE 240. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE COMPONENTS, 2018-2030 (USD MILLION)
TABLE 241. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 242. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY PRESERVATIVES, 2018-2030 (USD MILLION)
TABLE 243. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY STABILIZERS, 2018-2030 (USD MILLION)
TABLE 244. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 245. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISEASE BURDEN, 2018-2030 (USD MILLION)
TABLE 246. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 247. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 248. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 250. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY BIOTECH INNOVATIONS, 2018-2030 (USD MILLION)
TABLE 251. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 252. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY MARKET SIZE, BY MANUFACTURING PR

Companies Mentioned

  • Ablynx (A Sanofi Company)
  • AstraZeneca Plc (In collaboration with Sanofi)
  • Bavarian Nordic A/S
  • Codagenix, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • MedImmune (A subsidiary of AstraZeneca)
  • Meissa Vaccines, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • ReVax Ltd.
  • ReViral Ltd.
  • Sanofi S.A.
  • Valneva SE
  • Vaxart, Inc.
  • Zydus Cadila

Methodology

Loading
LOADING...

Related Topics

Related Reports

Respiratory Syncytial Virus Vaccine Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Respiratory Syncytial Virus Vaccine Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Respiratory Syncytial Virus (RSV) Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Respiratory Syncytial Virus Vaccine for Children Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Respiratory Syncytial Virus Vaccine for Children Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global, United States Global, United States
From
Respiratory Syncytial Virus (RSV) Therapeutics Market Report 2025 - Product Image

Respiratory Syncytial Virus (RSV) Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report - Product Image

Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.